Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
Have you noticed the many articles about Viagra are now appearing in the press - particularly the weekend press. It's now a cure-all for everything it seems - the articles hardly mention the ED need but how it can improve health, weight etc !
As a lth, I can’t see any serious growth in the sp happening until we get some solid profit figures. Yes the potential is enormous and all the omens point in the right direction but there continues to be a nervousness, probably because of the nature of the product that it could all come unstuck.
I’m so sorry for LTHs of which I was one once - paying several £s equivalent to today’s sp when Woodford was heavily into it. I sold out 2 years back at 44p - I couldn’t take the strain anymore. At even that sp I lost a bucketful.
Hope something turns up for you. ATB
Hi everyone - take this info as you will - please though Jamrock don’t see into this info any more than what it is. I’ve heard from a good source that sales are going well, not least Covid tests which have been very substantial- although we all know the margins are not what they were a couple of years back. The current sp is absurdly low and is less than the cash MHC has in the bank !
Email marketing is now being regularly done directly to individuals on their email database - I have received several emails including last month being offered a substantial discount on any purchases.
I would be pushing for more aggressive marketing but neither I or you are in charge so we must wait and see what management can achieve. But I do believe the company will eventually shine through. Like you I hope it will be soon but my contact tells me that good levels of sales are happening.
GLA
Your analysis PetitStVincent is nicely thought through and helpful. Thank you for that.
I'm not sure as to what 0.02p actually means in the context of today's Options announcement but I don't think it means 20p - isn't it a fraction of 1p or at maximum 2p ?
The point is the options are simply 'capitalist greed at the extreme' as the Directors/Senior management are paid well (in fact they've secured increases if the reports are examined) and here we have yet more options - some of which are immediately exercisable at a bountiful rate. Compare this with the last share placing that I subscribed for in 2021 of 40p per share. What about the Shareholders Mr Barder who have paid their way to your success ?
The Chinese angle , particularly Co-High needs some explanatory update given that is over 2 years that agreement was signed and we need to be told what is the holdup there - especially as it was felt the US FDA approval was a protracted exercise and yet has now been completed - so what is happening in China - solve that successfully (by which I mean profitably) Mr Barder and you could be thought worthy of yet more options.
In the meantime, I think today's announcement stinks !
It’s been a bad ride for so long now - I sometimes wish I’d never heard of MHC - I’m well under water with this share and thankfully ignored overtures to buy more.
That said today I received a marketing email from the company offering a £10 discount here’s what it said:
——————Quote:
MyHealthChecked Tests
Ready to unlock a healthier, happier you? Say hello to our new at-home health tests! With results that are simple to understand and easy to action, it's now more convenient than ever to get a clear perspective on your health.
🔓 Over 80 health areas to unlock
🧪3 test formats for your different needs
🏘️ Collect your sample at home
💖 Rated 'Excellent' on Trustpilot
£10off your first test
For a limited time only, we're offering our email subscribers, an EXCLUSIVE DISCOUNT when you shop on our website until the 30th October. Enjoy £10 off your first DNA or blood analysis test*. Just for you!
——————————
And I’ve noticed good Trustpilot reviews are starting to appear re. the various wellness tests. Whether this is a corner from which we can make a positive turn I’m still not sure - but I’m glad I’ve held back given how low the sp has gone.
Before we start writing MHC’s obituary it’s worth keeping things in perspective. Yes the CEO is arrogantly poor at communicating but the products are only just appearing in Boots. They are price point perfect and their packaging looks good.
There is cash in the bank to see them right through to next year. I have been negative but I still see a good future for them in the wellness market, a market in the UK which with our under pressure NHS will only grow very substantially.
Hold tight.
Disappointing news - would have been better to have released this July. Little factual information suggesting poor take up but it’s still early days. The cash burn has been well managed with there being £5m as at 30th June and clearly sufficient well into next year.
I’ve at last seen initial products on display (5} in my midsized but busy Boots. So I’ll be able to check how they’re doing. Can expect some sp weakness.
Reckon there must be a leak - what's new with AIM ?
It never hurts to chase the nominated advisor - especially if more of us do it. What effort does it take to do an email ?
myhealthchecked@walbrookpr.com
Just to reiterate the facts - the AGM statement RNS 11th May 2023 said there would be a trading update to shareholders in July. Even at this level of investment (AIM) it still matters if the MD or the Board miss a pre-declared date. Losing the CFO is not a valid reason - unless he's run off with the funds - and in fact all the more reason to keep to the promises.
Jamrock and any other concerned shareholders.
There's no denying the MD's somewhat disdain for shareholders as seen by missed follow-ups as to trading news. But here we have a definite missed date - July as declared by her in the May RNS.
I suggest an email to the company and/or their nominated broker asking why ?
Tefteresia - welcome to LSE but we are talking about the Trading Update not the Results.
2021 it was announced 7th July, for 2022 it was 20th July and more importantly, the MD announced in the May statement earlier this year:
"A trading update for the six months ended 30 June 2023 will be provided in July"
The MD is not good on keeping the shareholders up to date.
I think he’s had enough of working alongside Penny. She clearly has a strong personality and I suspect is difficult to be enthused with her style. We’ve seen it ourselves with the paucity of regular financial news.
Lucy Tobin aka The Tipster in Sunday Times headlined her piece this Sunday as 'Futura is looking for rapid growth'
She reminds readers that it has only 14 staff/directors working out of a small Surrey University Science park. She says that Futura has made a product that works and it is only just starting to shout about it. She makes clear things we might forget that Futura has minimised risk by outsourcing all it can; it does the science, but then, said James Barder, CEO "looks for commercial partners to do the rest." "We've done so in the UK, Europe and 7 countries in the Middle East. Saudi approval is expected in September - that's the biggest ED market in the Middle East." She was a day early for today's news re the US and probably thought like us it would fly.
It hasn't - but as sure as night follows day, unless male appendages start to shrink from too much Eroxon, then we are in for a sustained shareprice growth sooner or later. Initial sales at Boots were phenomenal - we know that - eventually these figures will become well known in the market and others will want their share of the action. Sit tight everyone our day is coming.
I notice last year's interim trading results for the 6 months to 30th June came out 20th July - which was a Wednesday. So perhaps this week we'll hear something.
I just hope it's substantive as so much that is said by the Board isn't frankly worth anything - I hesitate to say this but if we're honest with ourselves it could almost be described as 'waffle'. We're not getting specific numbers as to how these wellness products are performing. I understand Boots are showcasing the range in some large London/City stores but I haven't seen anything myself. Despite averaging down my breakeven is 27p and I'm sitting on quite a loss.
This can bounce on the right news but it's still looking a risky bet if the wellness isn't performing as we'd like to think it is. I was against the Consolidation as it doesn't by itself sort anything. Decent financial regular reporting to shareholders is all that matters in my opinion - let's hope this week we'll get decent news.
Bottom_feeder - I suspect you are right that Haleon has the better deal but that doesn't mean I have to agree with you as regards the future for us as shareholders in Futura. We've seen that slowly slowly we have made good progress with our link with Coopers in Europe and there is nothing at this stage to suggest otherwise when it comes to the US.
It's difficult to judge what Lombrad Odier's long-term ambitions are with FUM - to some extent that is holding the shareprice back - but once we have some financial data beyond just these upfront payments, as good as they are, we'll not really see the shareprice take off.
Brugge95 - the shareprice for FUM is quite an enigma.
Amazingly in years past the sp was higher than now when no trials had been completed - all on the promise that it would work. I can think back to 10 years ago paying the same price for the shares as now. I wonder if because of the nature of the principal product being one for a basic human use (we have yet to make any progress in the topical painkiller or cannabis compounds markets). Is the product too unsavoury, too seedy a background for many investors ?
Most new and upcoming businesses, see their sp making great strides early on, simply on imagined prospects whereas I've long felt that it is only on actual sales and profit figures that we will really see FUM's sp move. It's been a long game slowly unfolding with FUM, some will say it will happen once news of the US participant is announced but that's only one more step forward.
Once those financial figures are out and we can clearly see for ourselves it's not another emperor wearing new clothes (sorry to Hans Christian Andersen for bringing sex into your splendid parable) - then I'm quite sure the sp will rise and quickly go beyond £1 and this should become a true cash cow of a share. Until then, patience is the name of the game here - it will be rewarded I am quite sure. GLA
Tough call David ? I’m not sure it is as I think with the low take up shares lately there’s not a lot that will lift the sp until we get some sales news of the new products. As a lth myself we have seen these troughs before - by rights we should be pushing ahead rather than sinking but our profile isn’t high.
We have yet to see any meaningful reviews in Trustpilot on the new products , some of which have been on sale for many months. It is very frustrating at the moment.
They certainly appear to be BUYs as other smaller purchases were going through at around 59p Friday afternoon. So, if that is the case, why such a drop in the sp Friday to Monday ??
The medium term case for FUM is without doubt strong - the product is selling - we know that - and in very good volumes as far as we can tell. Is it MMs making a book for themselves or might we get a TR1 shortly that Lombard Odier have reduced their holdings ?